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Comparison of cytokeratin fragment 19 (CYFRA 
21-I), tissue polypeptide antigen (TPA) and 
carcinoembryonic antigen (CEA) as tumour markers 
in bronchogenic carcinoma 
M.-S. HUANG”, S.-B. JONG+, M.-S. TsAI*, M.-S. LIN+, I.-W. CHONG*, H.-C. LIN* AND 
J.-J. HWANG* 
“Division of Pulmonary Medicine, Department of Internal Medicine and ‘Department of Nuclear 
Medicine, Kaohsittng Medical College, Kaohsiung, Taiwan, Republic of China 
To elevate the diagnostic value of the serum cytokeratin 19 fragment (CYFRA 21-1) and compare it with 
carcinoembryonic antigen (CEA) and tissue polypeptide antigen (TPA) in bronchogenic carcinoma, the 
sera of 161 patients (58 with benign pulmonary disease and 103 with bronchogenic carcinoma) was 
investigated using immunoradiometric assay. 
Sensitivities for CYFRA 21-1, CEA and TPA (using 3.5 ng ml- ‘, 5.0 ng ml- ‘, 110 U l- ‘, respect- 
ively, cut-off values corresponding to a 95% specificity for benign pulmonary disease) in bronchogenic 
carcinoma were 64, 47 and 61%, respectively. Positive CYFRA 21-1 levels were identified in 75% of 
patients with squamous cell carcinoma (n=36), in 67% with adenocarcinoma (n=45), in 17% with large 
cell carcinoma (n=6), and in 50% with small cell lung cancer (SCLC) (n= 16). However, CYFRA 21-1 
levels were not significantly different between squamous cell carcinoma and the other histological types. 
The sensitivity of the combined measurement of CYFRA 21-1 with any other tumour marker was 
significantly higher than that of CYFRA 21-1 measurement alone. Elevated CYFRA 21-1 levels were 
observed in 44% of Stages I and II (n = 18) and 72% of Stages III and IV (n=69) patients with non-small 
cell lung cancer (PcO.05). A significant inter-marker correlation was observed between CYFRA 21-1 and 
TPA (n= 103, r=0.448, P~O.0001). Twenty-one patients were monitored by CYFRA 21-1, and 
significantly different changes in progressive patients (P=O*OO58) and regressive patients (PeO.016) were 
obtained. 
These results indicate that CYFRA 21-1 may be not only a sensitive tumour marker in the diagnosis 
of bronchogenic carcinoma, but also a useful marker for the monitoring of bronchogenic carcinoma. 
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Introduction 
Bronchogenic carcinoma is a major medical 
problem as its incidence is steadily increasing. 
In Taiwan, bronchogenic carcinoma is the most 
Received 20 October 1995 and accepted in revised form 
19 February 1996. 
Correspondence should be addressed to: M.-S. Huang, 
Associate Professor, Department of Internal Medicine, 
Kaohsiung Medical College, Kaohsiung, Taiwan, Republic 
of China. 
common cause of cancer death in women, and 
the secondary cause of cancer death in men 
(behind hepatoma). Several tumour markers, 
including carcinoembryonic antigen (CEA), tis- 
sue polypeptide antigen (TPA), squamous cell 
carcinoma antigen and neuron-specific enolase 
(NSE), in lung cancer have been reported in 
recent years (l-5). However, until now, none 
of the serum components proposed seems to 
be sensitive or specific enough to detect early 
disease (5-8). 
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Cytokeratins and other intermediate filaments 
of the cell-like vimentin and desmin are well 
known to be present in various physiological and 
pathological tissues (9-l 1). Moll et al. reported 
that all cytokeratins in their study are proteins 
restricted to epithelial cells alone (11,12). 
Recently, a new tumour marker called CYFRA 
21-1 has been described for the detection of 
the cytokeratin 19 fragment in serum (13-15). 
In addition, Broers et al. have also observed 
that cytokeratin 19 is particularly abundant in 
carcinoma of the lung (16,17). 
The aim of the present study was to evaluate 
the sensitivity of CYFRA 21-1 tumour marker 
in patients with bronchogenic carcinoma. The 
sensitivity of CYFRA 21-1 was also compared 
with the sensitivity of CEA and TPA. 
Materials and Methods 
PATIENT POPULATIONS 
Sera from 161 patients admitted to the Depart- 
ment of Internal Medicine of Kaohsiung 
Medical College Hospital between April 1993 
and April 1995 were included in this study. 
All patients with bronchogenic carcinoma, as 
defined by World Health Organization classifi- 
cation (18), were classified according to the 
United International Cancer Committee (UICC) 
staging system (19). Since this study was done 
retrospectively, all the sera was stored at - 70°C 
in the authors’ serum bank until analysis. 
MARKERS ASSESSMENT 
Serum CYFRA 21-1 assay values were deter- 
mined by means of a solid-phase double- 
determinant immunoradiometric assay (IRMA) 
(Centocor Diagnostic, Malvern, PA, U.S.A.) 
based on the two-site sandwich method. This 
assay utilizes two monoclonal antibodies (KS 
19-1 and BM 19-21) reactive with different 
epitopes expressed by cytokeratin subunit 19 
fragments, and is referred to as serum CYFRA 
21-1. KS 19-1 is coated on the solid phase, and 
the BM 19-21 antibody, radiolabelled with 1251, 
is used as the tracer. 
In addition to CYFRA 21-1, the following 
established tumour-associated antigens were also 
determined; TPA and CEA. The TPA levels 
were measured by immunoradiometric assay 
from Daiichi Laboratory (Tokyo, Japan) as 
described by the manufacturer. The CEA 
measurements were performed using a commer- 
cial kit (Abbott, North Chicago, IL, U.S.A.). 
The reference values were set at 5.0 ng ml - ’ 
for CEA (20), and at 110 U I- ’ for TPA (21) in 
the authors’ laboratory. 
STATISTICAL ANALYSIS 
The distribution of CYFRA 21-1, CEA and 
TPA was found to be non-Gaussian. Conse- 
quently, only non-parametric statistics were 
adopted (22). The Kruskal-Wallis one-way 
analysis of variance was performed to compare 
mean marker values of patients grouped accord- 
ing to histological type. Analysis of paired obser- 
vation of serum CYFRA 21-1 level in follow-up 
patients was done by Wilcoxon matched-paired 
signed-rank test. Proportions were compared 
by the Chi-square test. For testing significance, 
Student’s t-test was used. Correlation coefficients 
were assessed by Pearson’s linear regression 
analysis. Statistical significance was defined as 
P<O.O5. Sensitivity and specificity patterns were 
established by cumulative distribution analysis 
(23), which indicates the cut-off value of 95% 
specificity for benign pulmonary disease. 
Results 
Table 1 shows that 58 of 161 patients had benign 
pulmonary diseases (21 tuberculosis, 24 pneumo- 
nia, and 13 chronic obstructive pulmonary dis- 
ease). A total of 103 samples of sera were from 
patients with histologically proven bronchogenic 
carcinoma [36 squamous cell carcinomas, 45 
adenocarcinomas, six large cell carcinomas, and 
16 small cell carcinomas (SCLC)] were analysed 
(Table 1). 
BENIGN PULMONARY DISEASES 
In benign pulmonary disease, CYFRA 21-1 
serum assay values ranged from 9.1 to 
0.3 ngml-‘, the mean (SD) was 1.74 (l-55) 
ngml-’ (Table 2). No significant differences 
were observed among benign disease groups 
(P=O*18). The cut-off serum level of CYFRA 
21-l was 3.5 ng ml- ’ and there were three false 
positive cases (95% specificity). All of these three 
TABLE 1. Patients’ characteristics 
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Squamous cell carcinoma 
Adenocarcinoma 
Large cell carcinoma 
Small cell lung cancer 
Non-small cell lung cancer 
Stages I and II 
Stages III and IV 
161 
104157 













SD, standard deviation. 
patients with greater than 3.5 ng ml - ’ of serum 
CYFRA 21- 1 had pneumonia. 
BRONCHOGENIC CARCINOMAS 
The mean (SD) value of serum CYFRA 21- 1 in 
patients with bronchogenic carcinoma was 14.99 
(23.82) ng ml - ’ (range: 0.3-l 56.4 ng ml - ‘) and 
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was significantly higher then benign pulmonary 
diseases (Table 2, P<O*OOOl). The mean (SD) 
values of serum CYFRA 21-1 for non-SCLC 
and SCLC were 15.35 (24.36) and 13.08 (21.28) 
ng ml, respectively. However, the serum 
CYFRA 21-1 levels were not significantly higher 
in squamous cell carcinoma when compared 
with each of the other histological types 
(Table 2). 
The sensitivity of CYFRA 21-1, CEA and 
TPA in the 103 samples of bronchogenic carci- 
noma was 64, 47 and 61%, respectively. In 
non-SCLC patients, the sensitivity of serum 
CYFRA 21-1 in squamous cell carcinoma, 
adenocarcinoma and large cell carcinoma was 
75, 67 and 17%, respectively (Table 3). A 50% 
sensitivity for CYFRA 21-1 in SCLC was 
obtained. The sensitivity of CYFRA 21-1 was 
significantly higher in non-SCLC and SCLC 
than the sensitivity of CEA. However, there was 
no significant difference between the sensitivity 
of CYFRA 21-1 and TPA in bronchogenic 
carcinoma. 
The sensitivity and specificity of the combi- 
nations of CYFRA 21-1, TPA and CEA in 
bronchogenic carcinoma were analysed. When 
a combination of two markers was observed, 
the sensitivity of CYFRA 21-1 and/or TPA, 
CYFRA 21-1 and/or CEA, and CEA and/or 
TPA in bronchogenic carcinoma was 71, 77 and 
77%, respectively. The specificities were 63, 48 
and 40%, respectively. Eighty-two percent of the 
TABLE 2. Mean (SD) of serum cytokeratin fragment 19 (CYFRA 21-1) levels in benign and 
malignant pulmonary diseases 
CYFRA 21-1 (ng ml- ‘) 
n Range Mean (SD) 
Benign pulmonary diseases 58 9-l-0.3 1.74 (1.55) 
Bronchogenic carcinoma 103 156.4-0.3 14.99 (23.82)* 
Non-small cell lung cancer 87 1564-0.3 15.35 (24.36) 
Squamous cell carcinoma 36 86.7-0.3 17.28 (19.94)t 
Adenocarcinoma 45 1564-0.6 13.26 (25.11) 
Large cell carcinoma 6 105.7-0.7 19.34 (42.3 1) 
Small cell lung cancer 16 69.4-1.1 13.08 (21.28) 
*P<O.OOOl vs. benign pulmonary disease (Student’s t-test). 
*P>O.O5 vs. adenocarcinoma, large cell carcinoma, small cell lung carcinoma (one-way 
analysis of variance). 
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TABLE 3. Sensitivity (%) of cytokeratin fragment 19 (CYFRA 21-l) carcinoembryonic 
antigen (CEA) and tissue polypeptide antigen (TPA) in patients with bronchogenic 
carcinoma 
Cell types CYFRA 21-1 CEA TPA 
Non-small cell lung cancer 58/87 (67%)* 44187 (50%) 55/87 (63%) 
Squamous cell carcinoma 27/36 (75%)t 14/36 (39%) 25136 (69%) 
Adenocarcinoma 30/45 (67%) 26145 (58%) 29/45 (64%) 
Large cell carcinoma l/6 (17%) 4/6 (67%) l/6 (17%) 
Small cell lung cancer 8/16 (50%)* 4/16 (25%) 8/16 (50%) 
Total bronchogenic carcinoma 66/103 (64%)* 48/103 (47%) 63/103 (61%) 
Significantly higher than the sensitivity of CEA (P-=0.05) (Chi-squared test). 
tsignificantly higher than the sensitivity of CEA (BO.05) (Chi-squared test). 
Cut-off values: CYFRA 21-1 3.5ngml-‘; CEA 5.0ngml-‘; TPA llOI/Ul-‘. 
patients had at least one elevated tumour marker 
level. Normal values for all three tumour 
markers were found in 19 patients (18%). 
Although no significant difference among the 
different combinations of these three markers 
was obtained, the sensitivity of combined 
measurement of CYFRA 21-1 with any other 
tumour markers was significantly higher than 
the sensitivity of CYFRA 21-1 measurements 
alone (P<@O5). 
A significant inter-marker correlation was 
observed between CYFRA 21-1 and TPA (n = 
103, y=O+l8, P<O.OOOl). However, there was 
neither a correlation between CEA and CYFRA 
21-1 (n=103, y=O 025, P=O*O8), nor between 
CEA and TPA (n= 103, y=O*82, P=O*41). 
The sensitivity of CYFRA 21-1, CEA and 
TPA in non-SCLC by Stages I-IV is shown in 
Fig. 1. In Stages I and II, the sensitivity was 44% 
for CYFRA 21-1, 22% for CEA and 44% for 
TPA. The mean level and sensitivity of CYFRA 
21-1 were significantly higher in the advanced 
stages than in Stages I and II (P-=0-05). 
Serum CYFRA 21-1 assays were retrospec- 
tively analysed and subsequently compared with 
the results of clinical follow-up in 21 patients (17 
non-SCLC, four SCLC). Thirteen patients in 
Stages III and IV had progressive diseases in 
spite of receiving chemotherapy and/or radio- 
therapy, and subsequently revealed signifi- 
cant elevation of serum CYFRA 21-1 levels 
(Wilcoxon matched-paired signed-rank test: 
P=O*OO58, Fig. 2), although three of 13 patients 
had decreased serum CYFRA 21-1 levels. Eight 
patients (three Stage I and five Stage II) who 
received surgery and/or chemotherapy had 
clinical responses (complete response or partial 
response) to treatment, and showed the subse-2 
quent decline of serum CYFRA 21-1 levels’ 
(Wilcoxon matched-paired signed-rank test: 
P=O*O16, Fig. 2). Three squamous cell carci- 
noma patients and one adenocarcinoma patient 
underwent surgical treatment, and elevated 
CYFRA 21-1 levels were decreased. Four pa- 
tients responded to combination chemotherapy 
with declines in serum CYFRA 21-1 levels in 
three patients (two SCLC and one adeno- 
carcinoma), and elevation of serum CYFRA 









Stages I, II (n = 18) Stages III, IV h = 69) 
FIG. 1. Sensitivity (%) of cytokeratin fragment 19 
(CYFRA 21-l) stippled bars), tissue polypeptide 
antigen (TPA, hatched bars), carcinoembryonic 
antigen (CEA, solid bars) in bronchogenic 
carcinoma by stage of disease. 
\ 60 
0 
FIG. 2. Serum levels of cytokeratin fragment 19 
(CYFRA 21-1) assayed before and after the clinical 
response (complete response or partial response) or 
progression in patients with bronchogenic carci- 
noma (n=21). Statistical analysis by means of 
Wilcoxon matched-paired signed-rank test. 
*Patient received surgical treatment. 
Discussion 
Since the initial studies of CYFRA 21-1 were 
reported by Hasholzner et al. in 1992 (24), 
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CYFRA 21-l has been considered to be a new 
useful marker in the diagnosis of lung cancer, 
especially in squamous cell carcinoma (25-28). 
However, according to Stilber et al. (13) 
CYFRA 21-1 did not possess a significantly 
better profile than the other markers. To evalu- 
ate the usefulness of CYFRA 21-1 in the diag- 
nosis of bronchogenic carcinoma, 58 benign 
pulmonary diseases and 103 patients with pri- 
mary bronchogenic carcinoma were examined in 
the present study, and the sensitivity of CYFRA 
21-1 with CEA and TPA was compared. 
The best cut-off point of CYFRA 21- 1 value 
assayed by IRMA was set at 3.5 ng ml - ’ in this 
study. A comparison of the cut-off levels with 
various other CYFRA 21-1 studies (1525-28) 
is shown in Table 4. High specificity (95%) 
and sensitivity (64%) for CYFRA 21-1 were 
observed with the cut-off levels selected in this 
investigation. 
The serum CYFRA 21-l levels in benign 
pulmonary diseases were significantly lower than 
in bronchogenic carcinoma (P-=0*0001) and were 
not influenced by subgroups of benign pulmo- 
nary diseases (Table 2). Rastel et al. reported the 
same observation in 546 benign lung disease 
patients (25). Recently, Plebani et al. (26) found 
that serum CYFRA 2 1- 1 levels were significantly 
higher in patients with mesothelioma as com- 
pared with those who had benign pulmonary 
diseases, squamous cell carcinoma and SCLC. 
In bronchogenic carcinoma, the sensitivity of 
CYFRA 21-1 (64%) was significantly higher 
than the sensitivity of CEA (47%). However, 
there was no significant difference between 
CYFRA 2 l-l and TPA. The serum CYFRA 
TABLE 4. Comparison of sensitivity and specificity of cytokeratin fragment 19 (CYFRA 
21-1) measured by immunoradiometric assay in various studies 
No. of lung 





van der Gaast et al. (15 212 61 95 3.3 
Rastel et al. (25) 621 40 96 3,3 
Pujol et al. (27) 165 52 87 3,6 
Niklinski et al. (28) 98 56 96 3.6 
Rapellino et al. (29) 208 48 95 3.2 
Present study 103 64 95 3.5 
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21-1 in lung cancer showed higher sensitivity 
than the other markers (13,14,25). However, van 
der Gaast et al. reported similar sensitivities of 
CEA, TPA and CYFRA 21-1 (15). 
In non-SCLC, the sensitivity of CYFRA 21-1 
was significantly higher then the sensitivity of 
CEA, but it was not significantly higher than the 
sensitivity of TPA. Table 3 shows that serum 
CYFRA 21-1 was more sensitive for squamous 
cell carcinoma than for the other histological 
types, and similar observations have been 
reported by others (13,14,25,27-3 1). 
In SCLC, the sensitivity of serum CYFRA 
21-1 was 50% in this study. However, other 
reports (25,28-31) have shown a relatively low 
sensitivity of CYFRA 21-1 in SCLC. Similar 
observations have been reported (14,27,32). The 
case numbers and heterogeneity of SCLC might 
influence these results. 
To establish whether combinations of tumour 
markers could increase the sensitivity in the 
diagnosis of bronchogenic carcinoma, the com- 
binations of the sensitivity serum CEA, TPA and 
CYFRA 21-1 were analysed in the present study. 
The sensitivity of the combinations of CYFRA 
21-l and/or CEA, CEA and/or TPA, and 
CYFRA 21-1 and/or CEA and/or TPA was 
significantly higher than that of single CYFRA 
21-1. Steiber et al. (14) found that none of the 
combinations could improve the high CYFRA 
21-1 sensitivity; in contrast, Ebert et al. (31) and 
Plebani et al. (26) observed that the combined 
application of CYFRA 21-l and the other 
markers could significantly improve diagnostic 
sensitivity in lung cancer. 
From the present results, the sensitivity of 
CYFRA 21-1 was largely comparable to that 
of TPA. In addition, a significant inter-marker 
correlation was observed between CYFRA 21-1 
and TPA, but not between CEA and TPA, nor 
between CYFRA 21-1 and CEA. A good corre- 
lation between CYFRA 21-l and TPA has been 
confirmed by other studies (14,15). However, 
van der Gaast et al. (15) found a weak corre- 
lation between CEA and CYFRA 21-1 (n=212, 
y=O.28). Buccheri et al. (2,5) observed that there 
was no significant correlation between TPA and 
CEA. In accordance with the present results, a 
higher sensitivity for CEA was obtained in 
adenocarcinoma and large cell carcinoma. 
Therefore, CEA may be a useful lung cancer 
tumour marker in non-SCLC with normal 
CYFRA 21-1 or TPA serum values (25). 
A correlation between serum CYFRA 21-1 
and stage of the disease in non-SCLC was 
detected in other investigations (14,27-3 1). The 
mean level and sensitivity of CYFRA 21-1 were 
found to be significantly higher in the advanced 
stages (III and IV) in the present study. CYFRA 
21-1 could be a useful tumour marker in detect- 
ing more advanced lung cancer. Moreover, high 
sensitivity (44%) of CYFRA 21-1 in Stage I 
non-SCLC (26) has been reported, and CYFRA 
21-1 has been observed to the most sensitive 
marker to early lung cancer (26,30). Therefore, 
CYFRA 21-1 may be a useful and sensitive 
tumour marker in the diagnosis of bronchogenic 
carcinoma. 
The most important application of CYFRA 
21-1 will be in the monitoring of therapy. The 
value of CYFRA 21-1 for disease monitoring in 
the follow-up periods of 21 patients was exam- 
ined in the present study. Figure 2 shows that 
sequential CYFRA 2 1- 1 measurements appear 
to be of value in monitoring patients’ response to 
treatment. This finding is in accordance with 
other studies (25,27,28,30). 
In conclusion, CYFRA 21-1 may be not only 
a sensitive tumour marker in the diagnosis of 
bronchogenic carcinoma, but also a useful 
tumour marker for the monitoring of broncho- 
genie carcinoma. 
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